Overview

A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC

Status:
Enrolling by invitation

Trial end date:
2025-05-15

Target enrollment:

Participant gender:

Summary

The objective of this prospective, single-arm, single-center clinical study is to evaluate the efficacy and safety of envafolimab combined with platinum-containing dual-drug chemotherapy and recombinant human endostatin regimens for treating patients with operable II, IIIA, and IIIB (T3N2) stage NSCLC.

Phase:

Phase 2

Details

Lead Sponsor:

Second Xiangya Hospital of Central South University

Treatments:

Endostatins